Osteoporosis assessment and treatment in older patients who have sustained a hip fracture

Scottish Medical Journal

Volumn 51, Issue 2, 2006, Pages 32-35

  Lowdon, Douglas W ^a   Quinn, Catherine ^b   Mole, Pat ^c   Leese, Graham P ^c  

^a Section of Ageing and Health   (United Kingdom)

^b PERTH ROYAL INFIRMARY   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

Bone densitometry; Guidelines; Hip fracture; Older people; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; PARATHYROID HORMONE[1-34]; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM;

AGED; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE MINERAL; CONTROLLED STUDY; DRUG INDICATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FEMALE; GERIATRIC CARE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT REFERRAL; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SEX RATIO;

EID: 33646595927     PISSN: 00369330     EISSN: 00369330     Source Type: Journal    
DOI: 10.1258/RSMSMJ.51.2.32     Document Type: Article

References (22)

1. Cryer C, Patel S. Falls, fragility and fractures. National service framework for older people: The case for strategies to implement a joint heath improvement and modernisation plan for falls and osteoporosis. London: Alliance for Better Bone Health, 2001.
2. McClung MR, Geusens P, Miller PD, at al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:33-40.
3. Solomon D, Finkelstein JS, Katz J.N., et al. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 2003; 115:398-400.
4. Feldstein AF, Elmer PJ, Orwoll W et al. BMD measurement and treatment for osteoporosis in older individuals with fractures - a gap in evidence based guideline implementation. Arch Intern Med 2003; 163:2165-2171.
5. Freedman KB, Kaplan FS, Bilker WB, et al. Treatment of osteoporosis: are physicians missing an opportunity? J Bone Joint Surg 2000; 82 A:1063-70.
6. Torgerson DJ, Dolan P. Drug treatments that reduce fracture rate are underused after vertebral fractures. BMJ 1999; 318:1698.
7. Pal B. Questionnaire survey of advice given to patients with fractures. BMJ 1999; 318:500-501.
8. Elliot-Gibson V, Bogoch ER, Jamal SA, et al. Practise patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 2004; 15:767-778.
9. Scottish Intercollegiate Guideline Network. Prevention and Management of Hip Fracture in Older People. Publication no.56 Edinburgh; SIGN, January 2002.
10. Scottish Intercollegiate Guideline Network. Management of Osteoporosis. Publication no.71. Edinburgh; SIGN, June 2003.
11. British Orthopaedic Association Blue Book. The rare of fragility fracture patients. London; 2003.
12. Royal College of Physicians, London. Osteoporosis: Clinical guidelines update. London: RCP, 2001.
13. National Institute for Clinical Excellence. Bisphosphonates, selective oestrogen receptor modulators and parathyroid hormone for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology Appraisal 87. London: NICE, 2005.
14. McLellan AR, Gallacher SJ, Fraser M, et al. The fracture liaison service: success of a program for the evaluation and management of patents with osteoporotic fracture. Osteoporos Int 2003; 14:1028-1034.
15. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. Prepared by a working group in collaboration with the Royal College of Physicians, The Bone and Tooth Society of Great Britain, and the National Osteoporosis Society. London: Royal College of Physicians, 2002.
16. Harris ST, Watts NB, Genant HK, at al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with post menopausal osteoporosis: a randomised controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282:1344-52.
17. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on the risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077-82.
18. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-41.
19. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomised trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9:461-8.
20. Black DM, Palermo L, Nevitt MC, et al. Defining incident vertebral deformity: a prospective comparison of several approaches. J Bone Miner Res 1999; 14(1):90-101.
21. Simonelli C, Killeen K, Mehle S, et al. Barriers to osteoporosis identification and treatment among primary care physicians and orthopaedic surgeons. Mayo Clin Proc 2002; 77:334-8.
22. Solomon D, Morris C, Cheng H, at al. Medication use patterns for osteoporosis: An assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 2005; 80(2):194-201.